A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E–Deficient Mice [PDF]
, 2005 ObjectivesThe aim of this study was to investigate the antiatherogenic effects of the dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin (DFS).BackgroundThe new class of anti–type 2 diabetes drugs, dipeptidyl peptidase-4 inhibitors, improves ...
Matsubara, Junichi +18 more
core +1 more source
Asymmetric synthesis of γ-chloro-α,β-diamino- and β,γ-aziridino-α-aminoacylpyrrolidines and -piperidines via stereoselective Mannich-type additions of N-(diphenylmethylene)glycinamides across α-chloro-N-sulfinylimines [PDF]
, 2012 The asymmetric synthesis of new chiral gamma-chloro-alpha,beta-diaminocarboxylamide derivatives by highly diastereoselective Mannich-type reactions of N-(diphenylmethylene) glycinamides across chiral alpha-chloro-N-p-toluenesulfinylaldimines was ...
Augustyns, Koen +5 more
core +3 more sources
Molecules, 2018 Numerous studies indicate that diets with a variety of fruits and vegetables decrease the incidence of severe diseases, like diabetes, obesity, and cancer.
Poonam Kalhotra +3 more
semanticscholar +1 more source
Comprehensive Review of Analytical Methods for Quantifiable Estimation of Gliptins, Including Metformin, in Pharmaceutical and Bulk Dosage Forms [PDF]
E3S Web of ConferencesInsufficient insulin secretion or action leads to diabetes mellitus, causing chronic hyperglycemia and metabolic abnormalities. Metformin is a common medication recommended as first-line treatment for Type 2 DM, aiming to prevent complications and early ...
Dhruv Ashwini P., Vyas Dr. Amit kumar J.
doaj +1 more source
FEBS Open Bio, 2018 To clarify the effects of a dipeptidyl peptidase‐4 (DPP‐4) inhibitor on whole‐body energy metabolism, we treated mice fed a high‐fat diet (HFD) with teneligliptin, a clinically available DPP‐4 inhibitor.
Kenichiro Takeda +12 more
semanticscholar +1 more source
The pleiotropic cardiovascular effects of dipeptidyl peptidase‐4 inhibitors [PDF]
British Journal of Clinical Pharmacology, 2018 Patients with Type 2 diabetes have an excess risk for cardiovascular disease. One of the several approaches, included in the guidelines for the management of Type 2 diabetes, is based on dipeptidyl peptidase 4 (DPP‐4; also termed CD26) inhibitors, also called gliptins.
Avogaro, Angelo, Fadini, Gian Paolo
openaire +3 more sources
Acta Pharmaceutica Sinica B, 2014 Dipeptidyl peptidase 4 (DPP4) is recognised as an attractive anti-diabetic drug target, and several DPP4 inhibitors are already on the market. As members of the same gene family, dipeptidyl peptidase 8 (DPP8) and dipeptidyl peptidase 9 (DPP9) share high ...
Jinglong Liu +4 more
doaj +1 more source
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors [PDF]
, 2009 BACKGROUND: Type 2 diabetes is a chronic, progressive disease with a multi-faceted pathophysiology. Beyond the known defects of insulin resistance and beta-cell insufficiency, derangement of incretin hormones normally produced from the gut wall in ...
Berneis, K +4 more
core +1 more source
Henoch–Schönlein purpura induced by sitagliptin: A case report
SAGE Open Medical Case ReportsDipeptidyl peptidase-4 inhibitors are oral antihyperglycemic medications often used as adjuncts to other antidiabetic agents to treat type 2 diabetes mellitus.
Alexa Moschella, Carly Kirshen
doaj +1 more source
Ghrelin-O-Acyltransferase und Dipeptidylpeptidase-4: zwei mögliche neue Targets für die Therapie der Adipositas [PDF]
, 2019 Introduction. In light of the rapidly increasing prevalence of obesity and lack of pharmacological treatment options, a better understanding of feeding regulation is needed.
Teuffel, Pauline
core +1 more source